Tag:

Akebia Therapeutics

Latest Headlines

Latest Headlines

Biotech's breathless quarter of IPOs brings in $2.1B for R&D

Back in January, at the annual J.P. Morgan Healthcare Conference, across hotel lobbies and crowded hallways and standing-room-only cafes, one could hardly escape talk about the biotech IPO boom.

Biotechs bag $170M in IPO cash as a booming quarter winds down

Drug developers Akebia Therapeutics and MediWound banked a combined $170 million in their Wall Street debuts, stacking cash for their lead programs and taking advantage of a banner quarter for biotech IPOs.

Akebia swings for a $75M IPO to get its anemia drug into Phase III

Cambridge, MA's Akebia Therapeutics is lining up for a $75 million Wall Street debut, looking to raise cash and get its promising anemia drug into late-stage development.

Akebia snags $41M financing in anemia-drug race with GlaxoSmithKline, others

Today the company disclosed a $41 million Series C financing amid plans for a Phase IIb study later this year for AKB-6548, which is among a potential blockbuster class of oral drugs that could serve as safer alternatives to EPO therapies for anemia patients such as Amgen's Aranesp.

Cincy biotech spinoff snags $27M A round for vascular drug work

Aerpio Therapeutics, which split off from Akebia late last year, says it will use the money to fund a Phase Ib/IIa study of AKB-9778 for diabetic macular edema as well as a larger Phase II to hopefully nail down its proof-of-concept data.

Akebia lands $22M round for lead anemia program

Cincinnati, OH-based Akebia Therapeutics is pocketing $22 million in venture funds assigned to its second round. The money is being earmarked for work on new treatments for anemia and vascular